Exclusive Summary

• - Global IP barriers have fallen (US/EU key patents expired ~2015; biosimilars launched since 2018), enabling fast multi-region entry
• - Large, recurring demand: ~3–5 million patients annually qualify for primary prophylaxis, translating to ~12–30 million doses per year
• - Strong guideline endorsement (ASCO/ESMO/NCCN) and inclusion in WHO EML position pegfilgrastim as standard supportive care
• - Competitive but not saturated: ≥6 biosimilars in the US and ≥10 in the EU; room remains in emerging markets, tenders, and device-enabled differentiation (e.g., OBI)
• - With robust EU/US-GMP, full analytical similarity, and compliant PFS design, suppliers can win tenders with 60–80% price reductions while maintaining sustainable margins